



PRODUCT: **RECARBRIO™**

COMPANY: Merck & Co., Inc.

THERAPEUTIC AREA & INDICATION:

Combination anti-bacterial for adults with complicated urinary tract infections and complicated intra-abdominal infections

ABOUT THE PRODUCT

RECARBRIO™ is the only carbapenem/BLI combination addressing two of the three most critical antimicrobial-resistant bacteria on the WHO's priority list (carbapenem-resistant Enterobacteriaceae and *P. aeruginosa*). RECARBRIO™ is not subject to efflux from bacterial cells and provides a monotherapy treatment option for complex infections due to its unique coverage of gram-negative, gram-positive and anaerobic organisms. Innovative development of RECARBRIO™ with these novel attributes suggest it will be an important addition for the treatment of multidrug-resistant infections and will improve patient outcomes. The development of RECARBRIO™ demonstrates Merck's commitment to the fight against antimicrobial resistance a critical area of global public health.